Introduction
Non-small cell lung cancer (NSCLC) patients with sensitizing EGFR mutations, such as exon 19 deletions and L858R point mutations, are greatly responsive to the firstgeneration reversible EGFR tyrosine kinase inhibitors (TKIs) of gefitinib (Gef) and erlotinib without serious side effects. 1, 2 Several large Phase III clinical trials have confirmed the efficacy and safety of Gef, which has been recommended as the standard first-line treatment for advanced NSCLC patients harboring activating EGFR mutations. 3, 4 However, drug resistance greatly limits the efficacy of the EGFR-TKI treatment. The study of resistance to EGFR-TKIs in EGFR-mutant NSCLC patients can be divided into two broad categories: acquired and primary resistance. Acquired resistance refers to patients who invariably develop progressive disease following an initial objective response or a prolonged stable disease in ~9-13 months, 5 whereas primary resistance refers to patients who have progressive disease in <3 months or stable disease as the best response to EGFRTKIs. 6, 7 All patients with activating EGFR mutations who are initially responsive to EGFR-TKIs develop acquired resistance inevitably, while ~20%-30% of patients reveal primary resistance to EGFR-TKIs despite having tumors that harbor EGFR mutations. [8] [9] [10] [11] Resistance to EGFR-TKI treatment is a major obstacle in effective treatment of NSCLC. Therefore, our group engaged in identifying an effective, economical and safe combined therapeutic strategy to overcome drug resistance to EGFR-TKIs in NSCLC patients.
Metformin (Met) is a commonly used oral antihyperglycemic agent for type 2 diabetes mellitus (T2DM), displaying significant antitumor properties in various types of cancers including breast, prostate and ovary. [12] [13] [14] In the T2DM patients, Met treatment is associated with decreased incidence and mortality of cancer in comparison with other antidiabetic agents. 15 A retrospective observational trial from our group demonstrated that Met, in contrast with other hypoglycemic agents, combined with EGFR-TKI treatment was significantly associated with survival benefit outcome of advanced NSCLC patients with diabetes. 16 Previously, our group has confirmed that Met co-treatment with EGFR-TKIs could overcome acquired resistance, leading to strong inhibition on acquired resistance of NSCLC cells' proliferation, migration, and invasion synergistically. 17 However, it remains unknown whether Met may sensitize primary resistant NSCLC to EGFR-TKIs.
The molecular mechanisms associated with acquired resistance to EGFR-TKIs have been well documented. [18] [19] [20] [21] [22] On the other hand, there are only a few preclinical and retrospective reports on the mechanism of the primary resistance to EGFR-TKIs. It has been reported that de novo MET amplification, 23, 24 Bcl-2 interacting mediator of cell death (BIM)-deletion polymorphism, 25 phosphatase and tensin homolog (PTEN) loss 26 and de novo T790M mutation 27, 28 are associated with intrinsic resistance to EGFR-TKIs, but still a lot of primary resistance mechanisms are largely unknown. The insulin-like growth factor-1 receptor (IGF-1R) signaling activation has recently been reported to play a key role in primary resistance of EGFR-TKIs. 29 Having IGF1-positive serum indicated a negative prognosis in EGFR activating mutation in NSCLC patients who received Gef therapy. 30 EGFR-mutant NSCLC patients with de novo EGFR-TKI resistance showed a high expression of IGF-1R. 31 Here, our study demonstrated that compared to EGFR-TKI-sensitive cells (HCC827 and PC-9) and EGFR-TKI acquired resistant cells (PC-9GR and H1650-M3), the IGF-1R activity was much higher in EGFR-TKI primary resistant H1975 cells. However, primary resistance was attenuated upon incubation with the Gef and IGF-1R pathway inhibitor AG-1024 or when IGF-1R expression was reduced through RNA interference (RNAi). This treatment displayed reduction in phosphorylation of Akt kinase, the major downstream regulator of IGF-1R signaling, as well as upregulation of BIM and increased apoptosis potential in vitro. Met effectively increased the sensitivity of primary resistant H1975 cells to Gef, resulting in growth inhibition and apoptosis induction, via inhibiting IGF-1R signaling by regulating the AKT/BIM pathway. Furthermore, knockdown of IGF-1R expression incubation with siRNA abolished the synergistic effect of Met on Gef-induced cytotoxicity in H1975 cells. In addition, this combinational therapy reduced tumor masses much more effectively than Gef alone in a xenograft mouse model.
Materials and methods

Cell culture and reagents
EGFR-TKI-sensitive PC-9 cells were gifted by Prof. J. Xu and Dr. M. Liu from Guangzhou Medical University (China), and HCC827 cells were provided by the American Type Culture Collection. EGFR-TKI acquired resistant PC-9GR cells were gifted by Prof. J. Xu and Dr. M. Liu from Guangzhou Medical University (China), and H1650-M3 cells were kindly provided by Dr. R. Sordella from Cold Spring Harbor Laboratory. EGFR-TKI primary resistant H1975 cells were provided by the American Type Culture Collection. All the cells were cultured in the Roswell Park Memorial Institute 1640 medium (RPMI-1640; HyClone; HyClone, Logan, UT, USA) with Earle's salts and supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Waltham, MA, USA), 2 mM l-glutamine solution (Thermo Fisher Scientific), 100 U/mL penicillin (HyClone) and 100 μg/mL streptomycin sulfate (HyClone) at 37°C with 5% CO 2 in the air and 90% humidity. Gef (Iressa), purchased from Tocris Bioscience (Ellisville, MO, USA), and AG-1024, purchased from Selleck Chemicals (Houston, TX, USA), were prepared in dimethyl sulfoxide (DMSO) to obtain a stock solution of 10 mmol/L. Met (Sigma-Aldrich Co., St Louis, MO, USA) was dissolved in deionized water, and a 1 M stock solution 
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3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
Cytotoxicity of Gef plus Met was evaluated by the MTT dye reduction assay. A total of 2000 cells were plated in a 100 μL culture medium in 96-well microtiter plates. After 12 h incubation, Gef and 5 mM Met were added to each well as indicated, and the cells were further cultured for 48 h. Then, 10 μL of 5 mg/mL MTT reagent (Sigma-Aldrich Co.) in a 200 μL culture medium was added to each well. After 4 h, the medium was removed, and 150 μL of DMSO was admixed to each well to dissolve the formazan crystals. Absorbance was measured at a wavelength of 490 nm by using a ThermoFisher Spectrophotometer1510 (Molecular Devices LLC, Sunnyvale, CA, USA). Cell viability was determined by dividing the absorbance values of the treated cells with that of the untreated cells. Cytotoxic activity was recorded as IC 50 , which is the concentration necessary to reduce the absorbance of treated cells by 50% compared to the control (untreated cells). The experiments were conducted in triplicates.
Ki67 incorporation assay
Cell proliferation was also assessed by the Ki67 incorporation assay using a Ki67 labeling and detection kit (SigmaAldrich Co.). Briefly, cells were treated with Met or Gef, or both, for 48 h and then were incubated for 12 h with Ki67 (1:200 dilution) and fixed. Cell nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI) and then viewed with a live cell station (API DeltaVision, Rockville, MD, USA). At least 500 cells from three independent experiments were counted. The data obtained were expressed as the mean value of the percentage of positive cells ± standard error of the mean (SEM).
Calculation of combination index (CI) and data analysis
The isobolographic method was used to measure the type of interaction between Met and Gef. The CI was calculated for combinations of Met and Gef against H1975 cells, and the results were interpreted as described in the following:
where (Dx)1 = IC 50 of drug 1 (Met) alone; (D)1 = IC 50 of drug 1 (Met) in combination with drug 2 (Gef); (Dx)2 = IC 50 of drug 2 (Gef) alone; (D)2 = IC 50 of drug 2 (Gef) in combination with drug 1 (Met) and a = 0 for mutually exclusive or a = 1 for mutually nonexclusive modes of drug action.
Interpretation of results
Antagonism for CI value of >1.3, moderate antagonism for CI value of 1.1-1.3, additive interaction for CI value of 0.9-1.1, slight synergism for CI value of 0.8-0.9, moderate synergism for CI value of 0.4-0.6, and strong synergism for CI value of 0.2-0.4 were found.
Apoptosis assay
Flow cytometric analysis was used to detect apoptosis by examining altered plasma membrane phospholipid packing by the lipophilic dye Annexin V. Briefly, cells were treated with Gef and/or Met for 48 h, harvested by trypsin, washed twice with PBS and then resuspended at a density of 1 × 10 7 cells/mL. Thereafter, 5 μL of Annexin V-FITC and 5 μL of propidium iodide (PI) were added to 100 μL of the cell suspension and incubated for 30 min at room temperature in the dark. Next, labeled cells were processed by flow cytometry. All early apoptotic cells (i.e., Annexin V positive, PI negative), necrotic/late apoptotic cells (i.e., double positive) and living cells (i.e., double negative) were detected by using a Cytomics FC 500 flow cytometer (Beckman Coulter, Miami, FL, USA).
Transfection of siRNAs
H1975 cells were seeded at 40% cell confluency per well in six-well plates.
IGF-1R-specific siRNA used for IGF-1R knockdown and the control siRNA were synthesized by GenePharma (Shanghai GenePharma Co., Ltd.). The sequences of siRNA targeting the IGF-1R coding region were as follows: sense, 5'-GGAGAGAACUGUCAUUUCUTT-3' and antisense, 5'-AGAAAUGACAGUUCUCUCCTT-3'. The siRNAs were then transfected into the H1975 cells by HiPerFect Transfection Reagent (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
Western blot assay
Cells grown and treated as indicated were collected, and the total protein was extracted. The following primary antibodies were purchased from Cell Signaling Technology, Inc. (CST; Cambridge, MA, USA) and used: rabbit monoclonal anti-phosphorylated IGF-1R (Tyr1131), rabbit monoclonal anti-IGF-1R, rabbit monoclonal anti-AKT, rabbit monoclonal anti-phosphorylated AKT (Ser473), and rabbit monoclonal anti-Bim. Horseradish peroxidase-conjugated
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Animal experiments
For xenograft implantation, a total of 2 × 10 6 H1975 cells were injected subcutaneously into the back, next to the left forelimb of 6-week-old female BALB/cA-nu mice (Laboratory Animal Center of Third Military Medical University, Chongqing, China), all of which developed tumors with a size of 30 mm 3 within 5-7 days. The mice were then randomly assigned to two groups (eight mice/group) with or without oral administration of 1 mg/mL Met and 250 mg/L Gef in drinking water. Tumor volume was calculated as (length × width 
Statistical analysis
All data are presented as mean ± SD. Statistical analysis among the groups was analyzed by one-way analysis of variance (ANOVA) with a post hoc Bonferroni adjustment using Statistical Package for the Social Sciences (SPSS) software (version 21.0; SPSS Inc., Chicago, IL, USA), and statistical significance was assumed at an alpha value of p < 0.05.
Results
Primary resistance to EGFR-TKIs was more dependent on IGF-1R signaling pathway
We first detected the basal expression of p-IGF-1R, IGF-1R in a series of NSCLC cells. As shown in Figure 1 , although no obvious change was detected in the basal levels of total IGF-1R, EGFR-TKIs primary resistant H1975 cells exhibited higher levels of p-IGF-1R than acquired resistant cells (PC-9GR, H1650-M3) and sensitized cells (HCC827, PC-9). Our results demonstrated that primary resistance to EGFR-TKIs was more dependent on the IGF-1R pathway (Figure 1 ).
IGF-1R activation was responsible for EGFR-TKI primary resistance
To clearly identify whether IGF-1R signals contribute to the EGFR-TKI primary resistance, we used a small molecule chemical inhibitor of IGF-1R (AG-1024) against IGF-1R activity in H1975 cells. Western blot analysis showed that AG-1024 treatment indicated a specific reduction in phosphorylation protein levels of IGF-1R compared to control. When it was combined with Gef, IGF-1R activity was markedly suppressed despite the total-IGF-1R protein not being changed ( Figure 2D ).
Next, we further confirmed the effect of IGF-1R activity inhibitor using AG-1024 on H1975 cell proliferation. MTT assay was conducted to examine the growth inhibitory effect of AG-1024, Gef and combinational therapy on H1975 cells at 48 h of treatment. Results showed that AG-1024 induced a dose-and time-dependent decrease in cell viability of H1975 cells with IC 50 values of 43.6 ± 2.4 μM. Meanwhile, the indicated concentration of Gef alone determined a cytotoxic effect 
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Metformin overcomes primary resistance to EGFR-TKIs on H1975 cells with IC 50 values of 9.4 ± 0.74 μM; when it was combined with 20 μM of AG-1024, it showed a significant synergistic antiproliferative effect on H1975 cells with its IC 50 values dropping to 2.8 ± 0.2 μM (p = 0.00; Figure 2A and B). We also assessed the synergistic effect of IGF-1R inhibitor treatment in combination with Gef in H1975 cells through Ki67 incorporation assay. Ki67 labeling (as a percentage of total nuclei) was obviously reduced under combination treatment of AG-1024 and Gef ( Figure 2C) .
To investigate the possible mechanism by which IGF-1R signaling was inhibited on H1975 cells, the activities of IGF-1R downstream molecules were examined. Results showed the effects of single treatment with AG-1024 on inhibition of AKT activities and elevation of BIM protein level were modest, whereas the combination of AG-1024 and Gef substantially suppressed AKT activities and further induced apoptotic proteins of BIM ( Figure 2D ). These results demonstrated that co-treatment with AG-1024 and Gef could synergistically induce H1975 cells apoptosis by controlling AKT/BIM pathways.
These data indicated that IGF-1R activation was responsible for the proliferation of EGFR-TKI primary resistance 
Met sensitized H1975 cells to Gef
To evaluate the antiproliferative effect of Met on H1975 cells, we first performed MTT assays and found that Met could enhance the inhibitory action of Gef on the growth of H1975 cells, with IC 50 values varying from 9.41 ± 0.96 μM to 2.06 ± 0.60 μM ( Figure 3A and B) .
Considering Met could disrupt mitochondrial respiration, which may affect the MTT assay results, we further performed Ki67 incorporation assay and found that Met exhibited a profound synergistic inhibition effect on H1975 cells when it was combined with Gef ( Figure 3C ).
Next, we performed flow cytometry analysis to determine whether the drug combination could enhance apoptosis. Flow cytometric analysis demonstrated that few Met-treated cells or Gef-treated cells underwent apoptosis. However, combination therapy of Met with Gef markedly enhanced the apoptotic cells ( Figure 3D ). These results suggest that Met could sensitize H1975 cells to Gef by reducing cell viability and inducing cell apoptosis.
Cytotoxic effect of Met and/or Gef on H1975 cells
A dose-dependent inhibition of H1975 cells proliferation was observed after treatment with Met or Gef with IC 50 values of 21.44 mM or 9.41 μM, respectively (Table 1 
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Met decreased IGF-1R signaling activation in H1975 cells
IGF-1R signaling plays a key role in regulating the growth of H1975 cells, and IGF-1R inhibitor suppresses growth and induces apoptosis on H1975 cells. In addition, the combination of Met and Gef leads to inhibition of H1975 cells' proliferation and induction of apoptosis. To explore the mechanism underlying the antitumor effects of Met on H1975 cells, the effects of Met on IGF-1R signaling pathway were detected. We performed Western blot assay and found that Met alone inhibited IGF-1R activation and regulated its downstream signaling proteins such as suppressing p-AKT or escalating BIM, and Gef alone produced no significant change in the IGF-1R signaling pathway. After Met was combined with Gef, a more pronounced decrease in the protein levels of p-IGF-1R and p-AKT and increase in the protein levels of BIM were seen. These results show that Met promoted apoptosis of H1975 cells via regulating the IGF-1R/AKT/ BIM signaling pathway (Figure 4 ).
Met resensitized primary resistant H1975 cells to Gef highly dependent on IGF-1R signaling inhibition
To verify whether Met resensitizes EGFR-TKIs innate resistance cells to Gef through inhibiting IGF-1R signaling, IGF-1R siRNA was transfected into H1975 cells to downregulate IGF-1R expression. Western blot analysis showed a marked reduction of IGF-1R expression in H1975 cells transfected with si-IGF-1R RNA compared with those transfected with siRNA negative control (NC; Figure 5A ). As a result, downregulation of IGF-1R decreased p-AKT and increased protein of BIM. MTT assay analysis demonstrated that IGF-1R knockdown could partially recover sensitivity of H1975 cells to Gef in comparison with NC. In addition, co-treatment with Met and Gef inhibited the proliferation of IGF-1R knockdown cells and NC cells to a similar extent.
There was no significant difference in Gef sensitivity of 
Combinational regimen synergistically inhibited tumor growth of H1975 cell xenograft
Given the synergistic inhibitory effects of Met and Gef on H1975 cells' growth in vitro, it is believed that the combinational regimen has the potential to be highly effective in treating H1975 cells in vivo. Thus, we sought to determine the inhibition effect of Met and Gef on the tumor growth of H1975 cells xenograft. After 24 days, the xenograft tumors of the Gef group grew to an average volume of 2.19 ± 0.29 cm 3 starting from 0.05 ± 0.01 cm 3 . As shown in Figure  6A , addition of Met to Gef showed a significant synergistic inhibition of xenograft tumor growth from day 20 (p = 0.04) with an average volume of 0.95 ± 0.16 cm 3 . Moreover, gross appearances of xenograft tumors from the combination of Met and Gef, and Gef group are presented in Figure 6C . At the end of experiments, the tumors were isolated and weighed. Compared with the Gef group, the mean tumor weight was significantly less in the combinational group without affecting body weight obviously ( Figure 6B ).
Discussion
Primary resistance severely limits the clinical efficacy of first-generation EGFR-TKIs therapy, and understanding the mechanisms of this resistance is pivotal for developing more 
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Metformin overcomes primary resistance to EGFR-TKIs effective treatment strategies. Many studies have already reported that activation of the IGF-1R pathway potentially mediates acquired resistance to EGFR-TKIs. [33] [34] [35] [36] Our study provides similar evidence that EGFR-TKI-acquired resistant cell lines of H1650-M3 and PC-9GR exhibited high p-IGF-1R levels, whereas EGFR-TKI-sensitive cell lines of HCC827 and PC-9 had relatively lower levels of p-IGF-1R. To further examine the role of IGF-1R in primary resistance to EGFR-TKIs, we used the NSCLC H1975 cell line, which reproducibly carries EGFR L858R mutation and de novo EGFR T790M mutation. Our study demonstrated that IGF-1R activity of H1975 cells was found to be significantly, even higher than that of H1650-M3 and PC-9GR. We also conducted whole-exome sequencing of the H1975 cells; mutation status of Met, PI3KCA and PTEN loss was not observed. In NSCLC H1650 cells with deletion mutation on exon 19, which displays primary resistance to EGFR-TKIs due to exhibiting PTEN loss, 26 co-treatment of IGF-1R inhibitors such as α-IR3, AG-1024 or R1507 with Gef enhanced TKIinduced cells' growth inhibition and apoptosis.
37 Surprisingly, we found that IGF-1R inhibitor of AG-1024 sensitized H1975 cells, a primary resistance cell line with T790M mutation, to Gef by inducing apoptosis and inhibiting proliferation. Otherwise, knockdown of IGF-1R expression through siRNA could also enhance Gef sensitivity in H1975 cells. Hence, we further reinforce the significance of the deactivated IGF-1R signaling pathway that contributed to overcome EGFR-TKI primary resistance.
AKT signaling pathway plays an important role in cells' multiple biological activities, including proliferation and apoptosis. 38, 39 A clinical cancer gene test has described genomic alterations in the AKT pathway; increasing the kinase activity of AKT and contributing to cellular transformation may confer primary resistance to Gef. 40 IGF-1R can activate the EGFR-shared downstream signaling pathways, one of the signals being the PI3 kinase (PI3K)/AKT pathway. 41, 42 In this study, we selected the key marker of AKT in the shared downstream signaling pathways to verify the effect of IGF-1R inhibitor on the primary resistance to EGFR-TKIs in NSCLC. Our result showed that AG-1024 treatment alone or in combination with Gef suppressed IGF-1R inducement of p-AKT in H1975 cells; the dependence of AKT on IGF-1R signaling was further underscored by a knockdown of IGF-1R using siRNA. Thus, p-AKT status appears to be predominantly controlled by IGF-1R activation in H1975 cells. Of the BH3-only protein, BIM belonging to the Bcl-2 protein family may promote mitochondria releasing cytochrome c, which, in turn, may activate caspases, the key executioners of mitochondria-mediated apoptosis. 43, 44 AKT signaling pathway deactivation may lead to a substantial increase in BIM protein and induce apoptosis procedure consequently. 45, 46 Based on these studies, we found that downregulation of IGF-1R by siRNA induced expression of pro-apoptotic BH3 protein BIM and addition of AG-1024 to Gef increased the level of BIM protein and, thereby, induced mitochondriamediated apoptosis of primary resistant NSCLC H1975 cells.
In this study, we aimed to explore the effect of Met on EGFR-TKI primary resistance and the underlying mechanism. Our results showed that the combination of Met and Gef induced strong inhibition on H1975 cells' proliferation to a greater extent than either agent alone, and the apoptosis assay confirmed the synergistic inhibitory effect similarly. Combination of both agents caused a reduction in IC 50 values with clear synergistic effect. The enhancement of tumor growth suppression in the xenograft further supported the reverse effect of Met in primary resistant H1975 cells treated with Gef.
The fact that Met can inhibit growth of cancer cells is widely accepted, and the mechanism is associated with Met stimulating the activation of AMPK to inhibit mTOR phosphorylation 47, 48 and that Met can reduce IGF-1R signaling and suppress the PI3K/AKT/mTOR axis. 49, 50 Some studies have shown that Met inhibits IGF-1R signaling in cancer cells. [51] [52] [53] In addition, our group has reported that Met could restore crizotinib sensitivity in crizotinib-resistant NSCLC cells through inhibition of the IGF-1R signaling pathway. 54 To further explore the mechanism involved in the cytotoxicity effect of Met, we investigated the IGF-1R signaling pathway. We found that Met treatment alone or in combination with Gef could suppress IGF-1R signaling and subsequently inactivate AKT protein. To confirm the importance of the inhibitory effect of Met on IGF-1R in H1975 cells, we knocked down IGF-1R by siRNA and determined cell proliferation. As a result, knockdown of IGF-1R diminished the sensitization role of Met in H1975 cells. Caveolin-1 is reported to be required for Met inhibitory effect on IGF1 action in NSCLC. 55 In this context, whether caveolin-1 contributes to the synergistic inhibitory effect of Met on H1975 cells is deemed worthy of further study. Taken together, these results suggested the critical role of IGF-1R/AKT signaling in Met-regulated growth inhibition in H1975 cells, and Met-sensitized H1975 cells to Gef, via inhibition of mainly IGF-1R.
In the present study, we observed that after the H1975 cells were treated with Met alone, the protein level of BIM was increased and the combination of Met and Gef increased the BIM protein level to a greater extent. Consistent with our previous data, flow cytometry assay revealed that this submit your manuscript | www.dovepress.com
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Pan et al combination treatment effectively improved the apoptosis rate of H1975 cells. These results demonstrated that the antiproliferative synergistic effect of Met on H1975 cells with Gef was through inhibiting IGF-1R/AKT signaling, which consequently upregulated expression of BIM protein and promoted cell apoptosis through the activation of the mitochondrial pathway.
In addition, our laboratory has confirmed that for the sensitive cell lines PC-9 and HCC827, Gef alone could inhibit the p-EGFR activation; for the resistant cell lines PC-9GR and H1975, which harbor the T790M mutation, Gef showed poor performance, resulting in a high p-EGFR expression. Because Met treatment did inhibit the activation status of EGFR in NSCLC, 56, 57 it is possible that the role of Met in overcoming intrinsic resistance to EGFR-TKIs involves not only inhibiting IGF-1R signaling but also influencing the expression of p-EGFR.
Conclusion
Suppression of the IGF-1R pathway could restore EGFR-TKI primary resistant NSCLC H1975 cells' sensitivity to Gef, and synergistic antitumor effect was mediated through downregulation of p-AKT and escalation of BIM. We have reported the first evidence that Met inhibited IGF-1R signaling pathway and modulated AKT/BIM pathway, which contributed to the growth suppression and apoptosis induction role of Met, that potentiated the cytotoxicity effect of Gef in EGFR-TKI primary resistant H1975 cells. Moreover, the combination of Met and Gef showed greater inhibition of tumor growth than Gef alone in the xenograft. These findings provide a promising combined therapy strategy for the treatment of EGFR-TKI de novo resistant NSCLC.
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